Israel Launches National Trial of Psychedelic Drugs for PTSD

Israel's Ministry of Health is initiating a large-scale national clinical trial using psychedelic substances to treat post-traumatic stress disorder (PTSD), a move prompted by a severe mental health crisis following the October 7th attacks. The experiment will involve hundreds of patients who will receive two controversial substances, MDMA (the active ingredient in ecstasy) and psilocybin (found in magic mushrooms), under strict medical supervision. The trial, set to begin in the coming weeks and last approximately three years, aims to assess the efficacy of these drugs in improving the condition of patients with chronic, moderate to severe PTSD who have not responded to conventional treatments.

Since the war began, Israel has seen a significant rise in PTSD diagnoses. Current treatments, both pharmacological and trauma-focused psychological therapies, often fail to achieve full recovery, partly because patients struggle with the intense exposure to traumatic memories. A senior Ministry of Health official explained that the national approach was chosen to gain a better understanding of the substances' effectiveness and to offer new hope to patients whose current treatments are not progressing. The official noted that younger generations affected by the war are more open to novel treatment methods.

The psychedelic substances work by affecting neurotransmitter systems in the brain, such as serotonin and dopamine. They can rapidly induce altered states of consciousness and intense emotions, bringing suppressed memories to the surface in a way that allows patients to process them with greater acceptance and emotional flexibility. While MDMA and psilocybin are considered 'accelerants' for psychotherapy, they are not a cure-all. The official stressed that these are not magic bullets and that processing traumatic experiences is a complex and intensive process, distinct from recreational drug use.

The treatment protocol will follow a three-stage process: preparation sessions to build trust and teach coping mechanisms, the drug administration sessions themselves (lasting six to eight hours each, spaced weeks apart, in a clinic with medical staff), and integration sessions to process insights and connect them to daily life. The trial is also designed to prevent patients from seeking unregulated treatments on the black market, a growing concern due to limited experimental access and high demand. Strict controls are in place to prevent the diversion of the drugs, unlike the model for medical cannabis, where patients self-administer at home.

Ministry of Health officials emphasized that, unlike cannabis, these psychedelic compounds do not lead to daily stress reduction or physical dependence when used in a controlled clinical setting. The medication will be supplied by the hospital pharmacy and administered directly by a licensed therapist, ensuring patients have no physical contact with the drug and cannot accumulate doses at home.